225 related articles for article (PubMed ID: 2480794)
1. Caffeine, aminoimidazolecarboxamide and dicoumarol, inhibitors of NAD(P)H dehydrogenase (quinone) (DT diaphorase), prevent both the cytotoxicity and DNA interstrand crosslinking produced by 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) in Walker cells.
Roberts JJ; Marchbank T; Kotsaki-Kovatsi VP; Boland MP; Friedlos F; Knox RJ
Biochem Pharmacol; 1989 Nov; 38(22):4137-43. PubMed ID: 2480794
[TBL] [Abstract][Full Text] [Related]
2. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2).
Knox RJ; Boland MP; Friedlos F; Coles B; Southan C; Roberts JJ
Biochem Pharmacol; 1988 Dec; 37(24):4671-7. PubMed ID: 3144286
[TBL] [Abstract][Full Text] [Related]
3. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide).
Boland MP; Knox RJ; Roberts JJ
Biochem Pharmacol; 1991 Mar 15-Apr 1; 41(6-7):867-75. PubMed ID: 1901207
[TBL] [Abstract][Full Text] [Related]
4. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.
Knox RJ; Friedlos F; Jarman M; Roberts JJ
Biochem Pharmacol; 1988 Dec; 37(24):4661-9. PubMed ID: 3202902
[TBL] [Abstract][Full Text] [Related]
5. Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species.
Knox RJ; Friedlos F; Marchbank T; Roberts JJ
Biochem Pharmacol; 1991 Oct; 42(9):1691-7. PubMed ID: 1930294
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity.
Friedlos F; Biggs PJ; Abrahamson JA; Knox RJ
Biochem Pharmacol; 1992 Nov; 44(9):1739-43. PubMed ID: 1449531
[TBL] [Abstract][Full Text] [Related]
7. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9.
Walton MI; Smith PJ; Workman P
Cancer Commun; 1991 Jul; 3(7):199-206. PubMed ID: 1714284
[TBL] [Abstract][Full Text] [Related]
8. Role of redox cycling and activation by DT-diaphorase in the cytotoxicity of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB-1954) and its analogs.
Miŝkiniene V; Sergediene E; Nemeikaite A; Segura-Aguilar J; Cenas N
Cancer Lett; 1999 Nov; 146(2):217-22. PubMed ID: 10656629
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2).
Friedlos F; Jarman M; Davies LC; Boland MP; Knox RJ
Biochem Pharmacol; 1992 Jul; 44(1):25-31. PubMed ID: 1385952
[TBL] [Abstract][Full Text] [Related]
10. The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB 1954. Exceptional frequency and stability of the crosslink.
Friedlos F; Quinn J; Knox RJ; Roberts JJ
Biochem Pharmacol; 1992 Mar; 43(6):1249-54. PubMed ID: 1562278
[TBL] [Abstract][Full Text] [Related]
11. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase.
Knox RJ; Friedlos F; Sherwood RF; Melton RG; Anlezark GM
Biochem Pharmacol; 1992 Dec; 44(12):2297-301. PubMed ID: 1472095
[TBL] [Abstract][Full Text] [Related]
12. Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954.
Knox RJ; Friedlos F; Biggs PJ; Flitter WD; Gaskell M; Goddard P; Davies L; Jarman M
Biochem Pharmacol; 1993 Sep; 46(5):797-803. PubMed ID: 8373433
[TBL] [Abstract][Full Text] [Related]
13. CB 1954: from the Walker tumor to NQO2 and VDEPT.
Knox RJ; Burke PJ; Chen S; Kerr DJ
Curr Pharm Des; 2003; 9(26):2091-104. PubMed ID: 14529407
[TBL] [Abstract][Full Text] [Related]
14. Hepatic low-level chemiluminescence during redox cycling of menadione and the menadione-glutathione conjugate: relation to glutathione and NAD(P)H:quinone reductase (DT-diaphorase) activity.
Wefers H; Sies H
Arch Biochem Biophys; 1983 Jul; 224(2):568-78. PubMed ID: 6191666
[TBL] [Abstract][Full Text] [Related]
15. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase.
Maliepaard M; Wolfs A; Groot SE; de Mol NJ; Janssen LH
Br J Cancer; 1995 Apr; 71(4):836-9. PubMed ID: 7536024
[TBL] [Abstract][Full Text] [Related]
16. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.
Wu K; Knox R; Sun XZ; Joseph P; Jaiswal AK; Zhang D; Deng PS; Chen S
Arch Biochem Biophys; 1997 Nov; 347(2):221-8. PubMed ID: 9367528
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells.
Siegel D; Gibson NW; Preusch PC; Ross D
Cancer Res; 1990 Nov; 50(22):7293-300. PubMed ID: 2121335
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
Phillips RM
Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172
[TBL] [Abstract][Full Text] [Related]
19. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
Chen S; Knox R; Lewis AD; Friedlos F; Workman P; Deng PS; Fung M; Ebenstein D; Wu K; Tsai TM
Mol Pharmacol; 1995 May; 47(5):934-9. PubMed ID: 7746280
[TBL] [Abstract][Full Text] [Related]
20. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.
Knox RJ; Jenkins TC; Hobbs SM; Chen S; Melton RG; Burke PJ
Cancer Res; 2000 Aug; 60(15):4179-86. PubMed ID: 10945627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
